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Background
The affordability and financing of new, frequently
high-cost, medicines pose challenges to governments
world-wide. In Europe, the continual introduction of
new premium-priced medicines is of special concern
and requires adapted policy options. The aim of the
study was to survey whether and which pricing and
reimbursement policy options European countries have
implemented for new premium-priced medicines.
Methods
A cross-country survey was carried out through the instru-
ment of a Pharmaceutical Pricing and Reimbursement
Information (PPRI) query with policy-makers responsible
for pharmaceutical pricing and reimbursement in
42 countries, thereof all 28 European Union (EU) Member
States and nine further European countries. Responses
were received from 26 European countries and Canada
between February and March 2014.
Results
Most respondents reported that they had no specific defi-
nition for high-cost and/or premium-priced medicines in
their country, although they were clearly aware of the
issue. Most countries responded that they did not yet have
specific policies for the pricing and reimbursement of pre-
mium-priced medicines versus other medicines. Several
countries reported about the use of managed-entry agree-
ments, such as risk-sharing schemes and discount/rebate
arrangements. In addition, the relevance of Health
Technology Assessments (HTA) and pharmaco-economic
evaluations for these medicines was highlighted by some
countries. Countries were working on in-patient policies
in particular since high-cost and premium-priced medi-
cines are often used in the hospital setting. Some
European countries implemented specific funding models:
While medicines used in the in-patient sector are usually
funded out of the hospital budget (DRG funding), specific
high-cost and/or premium- priced medicines are financed
on an individual product basis (e.g. Belgium, Finland).
Another option is funding of such medicines out of special
funds (the Cancer Drugs Funds in England). Horizon
scanning was reported from a few countries (Canada, Italy,
the UK).
Conclusions
Although European governments were concerned with the
cost issue due to new medicines, specific pricing and reim-
bursement policies have yet to be thought through in a
systematic manner. Prioritization processes will increas-
ingly be required for the introduction of new medicines.
They should incorporate the principles of collaboration
and transparency: Cooperation between countries in
Europe and stakeholder dialogues could be further
strengthened. This needs to involve better balancing of the
value of innovation with equitable, affordable patient
access.
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